These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31186195)

  • 1. Experimental verification of factors influencing calcium salt formation based on a survey of the development of ceftriaxone-induced gallstone-related disorder.
    Ito R; Yoshida A; Taguchi K; Enoki Y; Yokoyama Y; Matsumoto K
    J Infect Chemother; 2019 Dec; 25(12):972-978. PubMed ID: 31186195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fasting and bed rest, even for a relatively short period, are risk factors for ceftriaxone-associated pseudolitiasis.
    Murata S; Aomatsu T; Yoden A; Tamai H
    Pediatr Int; 2015 Oct; 57(5):942-6. PubMed ID: 25907455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of ceftriaxone-associated biliary pseudolithiasis in adults: influence of renal dysfunction.
    Imafuku A; Sawa N; Sekine A; Kawada M; Hiramatsu R; Yamanouchi M; Hasegawa E; Hayami N; Hoshino J; Ubara Y; Takaichi K
    Clin Exp Nephrol; 2018 Jun; 22(3):613-619. PubMed ID: 29027036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftriaxone-associated Pseudolithiasis in Elderly People: Frequency and Risk Factors.
    Hotta K; Hashimura N; Takatsuka M; Matsuyama T; Nakagawa K; Yabusako T; Hosomi S; Fujiwara Y
    Intern Med; 2021; 60(24):3857-3864. PubMed ID: 34911872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Single-daily-dose treatment of ceftriaxone for biliary tract infections and bacterial counts in bile].
    Tanimura H; Maniwa Y; Okamoto M; Mukaihara S; Takabayashi A; Sato T; Henmi K; Yoshida K; Sawada H
    Nihon Geka Hokan; 1989 May; 58(3):299-309. PubMed ID: 2619435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Ceftriaxone-Associated Pseudolithiasis in Adults.
    Matsumi A; Tomoda T; Terasawa H; Fujii Y; Yamazaki T; Uchida D; Matsumoto K; Horiguchi S; Tsutsumi K; Kato H
    Digestion; 2023; 104(4):313-319. PubMed ID: 36907172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible Ceftriaxone-Induced Pseudolithiasis in an Adult Patient with Maintenance Hemodialysis.
    Shima A; Suehiro T; Takii M; Soeda H; Hirakawa M
    Case Rep Nephrol Dial; 2015; 5(3):187-91. PubMed ID: 26558252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed tomography findings of ceftriaxone-associated biliary pseudocholelithiasis in adults.
    Yoshida R; Yoshizako T; Katsube T; Kitagaki H
    Jpn J Radiol; 2019 Dec; 37(12):826-831. PubMed ID: 31654330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults.
    Iida S; Kinoshita H; Kawanishi T; Hayashi M
    Eur J Drug Metab Pharmacokinet; 2009; 34(2):107-15. PubMed ID: 19645220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of ceftriaxone-associated pseudolithiasis in an adult patient that disappeared after the discontinuation of ceftriaxone].
    Tomoda T; Ueki T; Saito S; Tatsukawa M; Nawa T; Hamamoto H; Endo H; Yabushita K; Shimoe T; Sakaguchi K
    Nihon Shokakibyo Gakkai Zasshi; 2013 Aug; 110(8):1481-6. PubMed ID: 23912008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chorea-like symptoms and high blood concentration of ceftriaxone in a patient undergoing hemodialysis: A case report.
    Yokoyama Y; Hosokawa N; Kudo T; Goda H; Ito K; Suzuki M; Funakoshi R
    J Infect Chemother; 2020 Mar; 26(3):285-288. PubMed ID: 31680037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing urinary calcium excretion after ceftriaxone and cephalothin therapy in adults: possible association with urolithiasis.
    Otunctemur A; Ozbek E; Polat EC; Cekmen M; Dursun M; Cakir SS
    Urolithiasis; 2014 Apr; 42(2):105-8. PubMed ID: 24310104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ceftriaxione, a third-generation cephalosporin, in pediatric patients.
    Fukumoto K; Aida S; Oishi T; Ueno K
    Biol Pharm Bull; 2009 Jul; 32(7):1139-41. PubMed ID: 19571374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the efficacy of ceftriaxone in acute suppurative otitis media and acute exacerbation of chronic suppurative otitis media. A comparative study with cefotiam as the control].
    Baba S; Mori Y; Suzuki K; Unno T; Kawabori S; Yanai T; Nonaka S; Takasaka T; Awataguchi T; Furuuchi I
    Jpn J Antibiot; 1989 Jan; 42(1):212-47. PubMed ID: 2523493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftriaxone-associated Pseudolithiasis in the Gallbladder and Bile Duct of an Elderly Patient.
    Yamabe A; Irisawa A; Wakabayashi H; Tsunoda T; Tominaga K
    Intern Med; 2020 Nov; 59(21):2725-2728. PubMed ID: 32669492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical studies on ceftriaxone in respiratory tract infections. CTRX Study Group].
    Shimada K; Kimura H; Kudoh S; Mohri M; Shiraishi T; Amano Y; Kurashima A; Uzawa T; Hisada T; Nagata T
    Jpn J Antibiot; 1993 Feb; 46(2):184-91. PubMed ID: 8331779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftriaxone-associated Biliary Pseudolithiasis with Elderly Type 1 Diabetes Mellitus: Two Case Reports.
    Kanazawa K; Suzuki S; Inaba T; Koga S; Kuwabara K
    Intern Med; 2023 Nov; 62(22):3367-3371. PubMed ID: 37032086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation of calcium, copper and iron levels in serum, bile and stone samples of patients having different types of gallstone: A comparative study.
    Khan M; Kazi TG; Afridi HI; Sirajuddin ; Bilal M; Akhtar A; Khan S; Kadar S
    Clin Chim Acta; 2017 Aug; 471():254-262. PubMed ID: 28625681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ceftriaxone in patients undergoing continuous renal replacement therapy.
    Goto K; Sato Y; Yasuda N; Hidaka S; Suzuki Y; Tanaka R; Kaneko T; Nonoshita K; Itoh H
    J Basic Clin Physiol Pharmacol; 2016 Nov; 27(6):625-631. PubMed ID: 27497425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetic and clinical evaluations of ceftriaxone in neonates and premature infants].
    Motohiro T; Oda K; Aramaki M; Tanaka K; Kawakami A; Shimada Y; Koga T; Tomita S; Sakata Y; Fujimoto T
    Jpn J Antibiot; 1988 Mar; 41(3):276-305. PubMed ID: 3404647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.